Results 41 to 50 of about 687 (125)

Successful management of bullous pemphigoid with dimethyl fumarate therapy: A case report

International Journal of Women's Dermatology, 2019
A 69-year-old woman affected by multiple sclerosis for 35 years was diagnosed with bullous pemphigoid (BP) and treated successfully with dimethyl fumarate (DMF) at a dose of 120 mg twice per day for 7 days and then increased to 240 mg twice per day after
Aslı Bilgic-Temel, MD, Shilpa Das, MD, Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD FRCP   +2 more
doaj   +1 more source

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study

Acta Dermato-Venereologica, 2023
is missing (Short communication)
Laura Gnesotto, Guido Mioso, Federico Bardazzi, Federica Filippi, Vito Di Lernia, Alberico Motolese, Sergio Di Nuzzo, Andrea Conti, Federica Arginelli, Monica Corazza, Giulia Odorici, Alessandro Borghi, Paolo Gisondi, Luigi Naldi, Paolo Dapavo, Aurora Parodi, Martina Burlando, Stefano Piaserico   +17 more
doaj   +1 more source

Spontaneous Non‐Catalyzed Molecular Reactions and Interactions in the Human Body: Biomedical Implications

Advanced Science, EarlyView.
ABSTRACT The human body functions as a natural reactor for a vast network of chemical and biological reactions and physical interactions among small molecules, proteins, cells, and numerous other components. These reactions/interactions are essential for maintaining normal physiological functions.
Yuhao Cai, Chao Zhao
wiley   +1 more source

Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question

Journal of Investigative Medicine High Impact Case Reports, 2020
Progressive multifocal leukoencephalopathy (PML) is a serious infective disease of the central nervous system that may occur in case of severe immunosuppression or after some treatment for multiple sclerosis (MS) with natalizumab, dimethyl fumarate, and ...
Stefania Federica De Mercanti MD, PhD, Dario Gned MD, Manuela Matta MD, Marco Iudicello MD, Emanuele Franchin MD, Marinella Clerico MD, PhD   +5 more
doaj   +1 more source

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

Advanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia, Hui You, Ke Zhang, Hui Jiang, Hongping Liu, Lianghua Liu, Aijie Zhang, You Zhou   +7 more
wiley   +1 more source

Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination

Clinical & Translational Immunology, 2023
Objectives Multiple sclerosis (MS) is a neurodegenerative disease characterised by inflammation and damage to myelin sheaths. While all current disease‐modifying treatments (DMTs) are very effective at reducing relapses, they do not slow the progression ...
Katharina Robichon, Rabia Bibi, Mackenzie Kiernan, Lisa Denny, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme   +6 more
doaj   +1 more source

Accelerating Primary Screening of USP8 Inhibitors from Drug Repurposing Databases with Tree‐Based Machine Learning

Advanced Intelligent Discovery, EarlyView.
This study introduces a tree‐based machine learning approach to accelerate USP8 inhibitor discovery. The best‐performing model identified 100 high‐confidence repurposable compounds, half already approved or in clinical trials, and uncovered novel scaffolds not previously studied. These findings offer a solid foundation for rapid experimental follow‐up,
Yik Kwong Ng, Sharon Ai Er Lam, Wei Chun Lim, Hannah Hui Min Toh, Shi Jun Ang   +4 more
wiley   +1 more source

Assessment of Total Side Effects of Oral Agents for the Treatment of Relapsing–Remitting Multiple Sclerosis Patients in Imam Khomeini Clinic in Hamadan [PDF]

Armaghane Danesh Bimonthly Journal, 2023
Background & aim: Three oral drugs, including fingolimod, dimethyl fumarate, and teriflunomide, which are clinically approved for the therapy of relapsing–remitting multiple sclerosis (RRMS) were reviewed in this work.
M Ghiasian, N Lashkari, M Mohammadi, Y Mohammadi, M Soleimani, R Mahjub, S Ataei   +6 more
doaj  

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source